SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED

Ratings Shanghai HeartCare Medical Technology Corporation Limited

Equities

6609

CNE100004MN5

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 08/05/2024 BST			5-day change	1st Jan Change
19.1 ^HKD	-0.10%		+6.70%	-35.80%

03-28	Shanghai HeartCare Medical Technology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai HeartCare Offloads Stake in Medical Device Developer Shenji Medical	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company shows low valuation levels, with an enterprise value at 0.75 times its sales.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 955 times its estimated earnings per share for the ongoing year.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED	-35.80%	93.24M	-
ABBOTT LABORATORIES	-4.66%	185B	C+
MEDTRONIC PLC	-1.01%	109B	C
BECTON, DICKINSON AND COMPANY	-4.20%	68.54B	A
DEXCOM, INC.	+2.68%	51.74B	B-
CENCORA, INC.	+9.12%	45.22B	B-
HOYA CORPORATION	+3.12%	41.74B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+4.13%	26.83B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+3.31%	26.69B	B
TERUMO CORPORATION	+11.62%	25.63B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes